Inotrope Therapy in Heart Failure

Rationale for Inotrope Use

The European Society of Cardiology recommends that inotropes should be reserved for patients with severe reduction in cardiac output resulting in compromised vital organ perfusion, which occurs most often in hypotensive acute heart failure 1, 2
Inotropes, especially those with adrenergic mechanisms like dobutamine, can cause sinus tachycardia and may induce myocardial ischemia and arrhythmias 1, 2
There is long-standing concern that inotropes may increase mortality in heart failure patients 1, 3

Norepinephrine is recommended as the first-line vasopressor due to fewer side effects and potentially lower mortality compared to dopamine 2
If additional inotropic support is needed beyond epinephrine, consider alternative agents such as milrinone or levosimendan rather than dobutamine 1
For patients on beta-blockers, levosimendan may be preferable to dobutamine to reverse the effect of beta-blockade 1, 2

Prolonged infusion of dobutamine (>24-48 hours) is associated with tolerance and partial loss of hemodynamic effects 4
Dobutamine increases the incidence of arrhythmias originating from both ventricles and atria, with this effect being dose-related 4
Multiple inotropes can lead to excessive tachycardia, myocardial ischemia, and increased myocardial oxygen demand 1, 2

If the patient has low systemic vascular resistance, consider adding a vasopressor such as norepinephrine instead of another inotrope 2
For patients with persistent hypotension despite adequate cardiac filling pressures and current inotropes, consider vasopressin as an additional agent 6, 2